MRI/PAI Dual-modal Imaging-guided Precise Tracking of Bone Marrow-derived Mesenchymal Stem Cells Labeled with Nanoparticles for Treating Liver Cirrhosis

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2023 Jan 16

PMID 36643042

Authors

Feng-Yong Liu

Ming Shi

Xin Li

Hong-Jun Yuan

Xiao-Mei Tian

Yi-Mao Xia

Min Zhou

Fu-Sheng Wang

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Stem cell transplantation is a potential treatment option for liver cirrhosis (LC). Accurately and noninvasively monitoring the distribution, migration, and prognosis of transplanted stem cells using imaging methods is important for in-depth study of the treatment mechanisms. Our study aimed to develop Au-FeO silica nanoparticles (NPs) as tracking nanoplatforms for dual-modal stem cell imaging.

Methods: Au-FeO silica NPs were synthesized by seed-mediated growth method and co-precipitation. The efficiency and cytotoxicity of the NPs-labeled bone marrow-derived mesenchymal stem cells (BM-MSCs) were evaluated by Cell Counting Kit-8 assays, ICP-MS, phenotypic characterization, and histological staining. The biodistribution of labeled BM-MSCs injected through different routes (the hepatic artery or tail vein) into rats with LC was detected by magnetic resonance imaging (MRI), photoacoustic imaging (PAI), and Prussian blue staining.

Results: Synthesized Au-FeO silica NPs consisted of a core (star-shaped Au NPs) and an outside silica layer doped with FeO NPs. After 24 h coincubation with 2.0 OD concentration of NPs, the viability of BM-MSCs was 77.91%±5.86% and the uptake of Au and Fe were (22.65±1.82) µg/mL and (234.03±11.47) µg/mL, respectively. The surface markers of labeled BM-MSCs unchanged significantly. Labeled BM-MSCs have osteogenic and adipogenic differentiation potential. Post injection , rat livers were hypointense on MRI and hyperintense on PAI. Prussian blue staining showed that more labeled BM-MSCs accumulated in the liver of the hepatic artery group. The severity of LC of the rats in the hepatic artery group was significantly alleviated.

Conclusions: Au-FeO silica NPs were suitable MRI/PAI dual-modal imaging nanoplatforms for stem cell tracking in regenerative medicine. Transhepatic arterial infusion of BM-MSCs was the optimal route for the treatment of LC.

References

Fang X, Lui K, Li S, Lo W, Li X, Gu Y . Multifunctional Nanotheranostic Gold Nanocage/Selenium Core-Shell for PAI-Guided Chemo-Photothermal Synergistic Therapy in vivo. Int J Nanomedicine. 2020; 15:10271-10284. PMC: 7751612. DOI: 10.2147/IJN.S275846. View

Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolahzadeh L . In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol. 2011; 38(7):961-7. DOI: 10.1016/j.nucmedbio.2011.03.008. View

Ross C, Ang D, Almeida-Porada G . Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis. Front Immunol. 2019; 10:266. PMC: 6409305. DOI: 10.3389/fimmu.2019.00266. View

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

Cao Y, Gang X, Sun C, Wang G . Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer. J Diabetes Res. 2017; 2017:9328347. PMC: 5366201. DOI: 10.1155/2017/9328347. View

Mushahary D, Spittler A, Kasper C, Weber V, Charwat V . Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2017; 93(1):19-31. DOI: 10.1002/cyto.a.23242. View

Smith A, Baumgartner K, Bositis C . Cirrhosis: Diagnosis and Management. Am Fam Physician. 2019; 100(12):759-770. View

Hirao H, Nakamura K, Kupiec-Weglinski J . Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity. Nat Rev Gastroenterol Hepatol. 2021; 19(4):239-256. DOI: 10.1038/s41575-021-00549-8. View

Wu K, Su D, Liu J, Saha R, Wang J . Magnetic nanoparticles in nanomedicine: a review of recent advances. Nanotechnology. 2019; 30(50):502003. DOI: 10.1088/1361-6528/ab4241. View

10.

Cai J, Zhang X, Wang X, Li C, Liu G . In vivo MR imaging of magnetically labeled mesenchymal stem cells transplanted into rat liver through hepatic arterial injection. Contrast Media Mol Imaging. 2008; 3(2):61-6. DOI: 10.1002/cmmi.231. View

11.

Moon K, Suh H, Kim K, Han S, Young K, Lee J . Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers. Diabetes. 2019; 68(4):837-846. DOI: 10.2337/db18-0699. View

12.

Hong Y, Xu H, Yang Y, Zhou S, Jin A, Huang X . Isolation and Cultivation of Mandibular Bone Marrow Mesenchymal Stem Cells in Rats. J Vis Exp. 2020; (162). DOI: 10.3791/61532. View

13.

Karvellas C, Francoz C, Weiss E . Liver Transplantation in Acute-on-chronic Liver Failure. Transplantation. 2020; 105(7):1471-1481. DOI: 10.1097/TP.0000000000003550. View

14.

Kim D, Kim J, Park Y, Lee N, Hyeon T . Recent Development of Inorganic Nanoparticles for Biomedical Imaging. ACS Cent Sci. 2018; 4(3):324-336. PMC: 5879478. DOI: 10.1021/acscentsci.7b00574. View

15.

Kang N, Xu D, Han Y, Lv X, Chen Z, Zhou T . Magnetic targeting core/shell FeO/Au nanoparticles for magnetic resonance/photoacoustic dual-modal imaging. Mater Sci Eng C Mater Biol Appl. 2019; 98:545-549. DOI: 10.1016/j.msec.2019.01.013. View

16.

Vizoso F, Eiro N, Costa L, Esparza P, Landin M, Diaz-Rodriguez P . Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities. Int J Mol Sci. 2019; 20(15). PMC: 6696100. DOI: 10.3390/ijms20153738. View

17.

Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M . Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019; 39:18. PMC: 6732839. DOI: 10.1186/s41232-019-0107-z. View

18.

Zhu M, Hua T, Ouyang T, Qian H, Yu B . Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice. Stem Cells Int. 2021; 2021:6546780. PMC: 8380491. DOI: 10.1155/2021/6546780. View

19.

Eggenhofer E, Luk F, Dahlke M, Hoogduijn M . The life and fate of mesenchymal stem cells. Front Immunol. 2014; 5:148. PMC: 4032901. DOI: 10.3389/fimmu.2014.00148. View

20.

Li Y, Shen S, Shao T, Jin M, Fan D, Lin A . Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6C macrophages through activating the cytokine-paracrine and apoptotic pathways. Cell Death Discov. 2021; 7(1):239. PMC: 8437974. DOI: 10.1038/s41420-021-00584-z. View